Physician profile
Ryan S Conrad
NPI 1346289402
$25,707.01
in general payments reported to CMS, 2019-2025
84 companies · $5,353 in 2025
The $5,353 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,095 · 2020: $1,781 · 2021: $2,443 · 2022: $2,991 · 2023: $5,046 · 2024: $4,999 · 2025: $5,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Travel and Lodging: $860 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $246 · Education: $50.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,241.14 |
| Travel and Lodging | $859.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $245.58 |
| Education | $50.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,285.16 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Inspire Medical Systems, INC. | $1,622.64 | 2022-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $1,389.86 | 2019-2025 | |
| Genzyme Corporation | $1,168.69 | 2019-2025 | |
| Biogen, INC. | $1,109.60 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $1,071.90 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Lilly USA, LLC | $1,054.16 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Tg Therapeutics, INC. | $1,019.74 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $988.07 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $924.44 | 2021-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $838.32 | 2020-2025 | Valtoco |
| Celgene Corporation | $832.16 | 2020-2025 | Zeposia |
| Sk Life Science, INC. | $787.03 | 2020-2025 | Xcopri |
| Mdd US Operations, LLC | $765.46 | 2019-2025 | Apokyn, Apokyn, Xadago |
| Pfizer INC. | $716.07 | 2023-2025 |
Show all 84 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Conrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.